Treatment Pattern of NOACs (Non-vitamin K Oral Anticoagulants) in Outpatient Users in Colombian Databases
Completed
- Conditions
- Atrial Fibrillation
- Registration Number
- NCT03474757
- Lead Sponsor
- Bayer
- Brief Summary
This population-based descriptive study will characterize first-time users of three NOACs (rivaroxaban, dabigatran and apixaban) in prevention of stroke in non-valvular atrial fibrillation (SPAF) patients and will assess the patterns of drug utilization in routine general practice in Colombia
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 10528
Inclusion Criteria
- First prescription of NOACs (rivaroxaban, dabigatran and apixaban) in the outpatient setting.
- Non valvular Atrial Fibrillation (NVAF) Patients
- aged ≥18 years
- at least one year of enrollment in the Audifarma database
- one year since first encounter with healthcare provider will be included in the study
Exclusion Criteria
- Patients with any record of index drug prescription prior to the enrolment period.
- Patients who qualify as members of more than one cohort study on the same day
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Sex At Baseline Proportion of Naive to non-naive patient At Baseline Duration of treatment Up to 6 years Discontinuation Up to 6 years Co-morbidity At Baseline Healthcare utilization Up to 2 years Primary Care Physicians visits, Outpatient visits and Hospital admissions
Dose at first prescription Up to 6 years Switch to another study drug Up to 6 years Age At Baseline
- Secondary Outcome Measures
Name Time Method Time trends of usage of study medications Up to 6 years
Trial Locations
- Locations (1)
Many Locations
🇨🇴Multiple Locations, Colombia
Many Locations🇨🇴Multiple Locations, Colombia